Journal
ADVANCED THERAPEUTICS
Volume 4, Issue 2, Pages -Publisher
WILEY
DOI: 10.1002/adtp.202000226
Keywords
drug delivery; microbes; polymeric films; process development; scale-up
Categories
Funding
- National Institute of Diabetes and Digestive and Kidney Diseases of the National Institutes of Health [R21DK123583]
- National Center for Advancing Translational Sciences of the National Institutes of Health [UL1TR002489]
- National Science Foundation as part of the National Nanotechnology Coordinated Infrastructure, NNCI [ECCS-1542015]
Ask authors/readers for more resources
LBPs are a new therapeutic modality, with feces-derived microbial consortiums being the main focus, but there are also subsets that use batch culture for individual microbial strains. Delivery formulations like polymer encapsulation are being developed for LBPs, requiring distinct manufacturing processes. A streamlined approach called BCF combines batch culture and formulation processes into a single step, reducing the number of required steps for LBP-film formulation.
Live biotherapeutic products (LBPs) are an emerging therapeutic modality that have been clinically investigated for treating pathogenic infections and inflammatory diseases. A major class of LBPs are feces-derived microbial consortiums which require numerous process development steps (e.g., separation, purification, blending) to facilitate LBP formulation into oral dosage forms. A subset of these LBPs circumvents the need for continuous fecal processing by batch culture for individual strains of microbes that are rationally defined and combined in the final LBP formulation. Separately, delivery formulations (e.g., polymer encapsulation) are being developed for LBPs to improve storage and intestinal engraftment; however, formulation requires additional manufacturing processes distinct from fecal processing or batch culture. Here, a streamlined approach termed batch culture formulation (BCF) is developed to combine the individual batch culture and formulation processes into a single-step process. Based on a previously described polymeric film formulation that encapsulates LBPs, BCF is shown to reduce the number of required processes to formulate LBP-films without altering LBP phenotype, function, or storage profiles compared to the standard LBP-film formulation approach. Additionally, it is demonstrated that BCF facilitates scaled-fabrication from the milligram to gram scale with predictable loading, highlighting the potential that BCF has for clinical translation.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available